CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 239 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01400425
NCT01400425Phase 3Completed
CompareCT.gov

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Avid Radiopharmaceuticals·interventional·Posted Jul 22, 2011·Updated Mar 29, 2013

In Brief

A Phase 3 clinical trial evaluating florbetapir F 18 for Progressive Cognitive Decline. Completed, enrolled 239 participants across 18 sites.

Detailed Summary

The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Cognitive Decline
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 22, 2011
Enrollment StartJul 1, 2011
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.9 years ago

Interventions

florbetapir F 18drug

IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose